Loading
A phase 3 trial of panitumumab and bevacizumab (glioblastoma use) in colorectal cancer, run by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), active but no longer recruiting.
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer is a phase 3, randomised interventional study registered as NCT03635021 by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), with a registry enrolment figure of 419 participants, started 2018-10-15 and due to reach its primary completion in 2025-06-28. Interventions recorded: FOLFOX regimen; Panitumumab; Bevacizumab; FOLFIRI regimen. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival rate at 35 months. Colorectal eligibility wording from the registry: "Histologically confirmed adenocarcinoma of the left colon or rectum (originate in the splenic flexure, descending colon, sigmoid colon, or rectum) in patients with unresectable (not amenable to radical surgery of metastases at the study inclusion) metastatic (M1) disease". Sites: Spain. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bevacizumab (glioblastoma use), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Panitumumab, Bevacizumab (glioblastoma use), Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/